1-2 of 2
Grigoriy B Rekhtman
Close
Sort by
Journal Articles

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

Kamil Kaplanov, Andrey Zaritskiy, MD, Sergey Alexeev, MD, PhD, Elena Volodicheva, Alexander Loginov, MD, Rashida Orlova, MD, PhD, Victoria Dvornichenko, MD, PhD, Marina Kosinova, MD, Olga Serduk, Vladimir Milovanov, MD, Alexander Myasnikov, MD PhD, Shekar Patil, MD, Shekar Patil, MD, Bharath Rangarajan, MD, Senthil Jagannathan Rajappa, MD DM, Minish Jain, MD, Sharanabasappa Nirni, MD, PhD, Akhil Deka, M, Grigoriy B Rekhtman, Iryna Kryachok, Zvenyslava Maslyak, Ekaterina Chernyaeva, MD, Roman Ivanov, MD, PhD, Alexander Isaev, MD
Journal: Blood
Blood (2014) 124 (21): 5467.
https://doi.org/10.1182/blood.V124.21.5467.5467
Published: 2014
Journal Articles

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

Philippe Moreau, Halyna V Pylypenko, Sebastian Grosicki, Evgeniy E Karamanesht, Xavier Leleu, Maria E Grishunina, Grigoriy B Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna V Shubina, Jean-Paul Fermand, Martin Kropff, James Cavet, Sudha Parasuraman, Huaibao Feng, Donna M Skee, Helgi van de Velde, William M Deraedt, Jean-Luc Harousseau
Journal: Blood
Blood (2010) 116 (21): 312.
https://doi.org/10.1182/blood.V116.21.312.312
Published: 2010